Nathan Peterson, MD
Hematology & Oncology · Provo, UTNPI 1194135350
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,216 of the $2,775 with a category attached, or 79.9%. It is spread thinly across 28 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,700 and has fallen 98.8% since, to $21 in 2024. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 133 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$325
- AstraZeneca$258
- Johnson & Johnson$257
- Pfizer$216
- Lilly USA, LLC$201
- Bristol Myers Squibb$198
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$1505%
- Food & beverage$2,21680%
- Education$40915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 19 | $325 |
| AstraZeneca(2 entities) | 8 | $258 |
| Johnson & Johnson(2 entities) | 7 | $257 |
| Pfizer | 18 | $216 |
| Lilly USA, LLC | 16 | $201 |
| Bristol Myers Squibb | 7 | $198 |
| Seagen Inc. | 6 | $148 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $139 |
| Amgen | 3 | $133 |
| Gilead(2 entities) | 3 | $130 |
| Novartis | 6 | $122 |
| Incyte Corporation | 5 | $105 |
| Daiichi Sankyo Inc. | 4 | $96 |
| Stemline Therapeutics Inc. | 3 | $71 |
| Foundation Medicine, Inc. | 3 | $44 |
| GSK | 2 | $44 |
| Taiho Oncology, Inc. | 3 | $40 |
| Genentech USA, Inc. | 2 | $38 |
| AbbVie | 2 | $37 |
| Tesaro, Inc. | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Dova Pharmaceuticals | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Secura Bio, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Bayer | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
How this compares
$2,775 in reported general payments places this provider in the 50th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 12 | $222,777 |
| IbrancePalbociclib | 13 | $194,455 |
| OrgovyxRelugolix | 12 | $32,537 |
| Abiraterone Acetate | 88 | $17,362 |
| EliquisApixaban | 15 | $8,985 |
| Anastrozole | 148 | $2,468 |
| Exemestane | 12 | $725 |
| Hydroxyurea | 25 | $671 |
| Prednisone | 104 | $511 |
| Acyclovir | 31 | $429 |
| Potassium Chloride | 29 | $428 |
| Ondansetron OdtOndansetron | 35 | $388 |
| Dexamethasone | 16 | $384 |
| Gabapentin | 25 | $349 |
| Alendronate Sodium | 52 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $44 | $222,77712 claims |
| PfizerIbrance, Eliquis | $216 | $203,44028 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $11 | $42931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Provo
- Nathan RichProvo$14K
- Marc NuttallProvo$12K
- Steven WallentineProvo$7K
- Brandt EsplinProvo$4K
- Daniel SimsProvo$2K
- David RirieProvo$1K
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.